Effective Design of Clinical Trials | FDA

The 1962 FD&C Act

Prior to 1962, drug safety was the primary concern, but the act revolutionized the landscape by demanding substantial evidence of a drug’s effectiveness.

This shift led to the requirement of “adequate and well-controlled studies” – a cornerstone of modern clinical research.


𝗔𝗱𝗲𝗾𝘂𝗮𝘁𝗲 𝗮𝗻𝗱 𝗪𝗲𝗹𝗹-𝗖𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗱 𝗦𝘁𝘂𝗱𝗶𝗲𝘀: 𝗧𝗵𝗲 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹

These studies form the basis for drug approval and must meet several criteria:

  • A clear statement of objectives and a detailed description of analysis methods.
  • A valid comparison with a control group to assess drug effects accurately.
  • Minimization of bias and sufficient detail to ensure transparency and critical evaluation.
  • Adequate measures to minimize bias from subjects, observers, and analysts.


𝗧𝘆𝗽𝗲𝘀 𝗼𝗳 𝗖𝗼𝗻𝘁𝗿𝗼𝗹𝘀: 𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀

Various types of controls are used in clinical trials, each with its advantages and limitations:

Placebo Control:
Compares the test drug to an inactive substance, providing a baseline for drug effect assessment.

No Treatment Control:
Used when objective measurements are available and placebo effects are negligible.

Dose-Response Control:
Compares different doses of the drug to determine effectiveness and identify optimal dosage.

Active Control:
Compares the test drug to an existing effective treatment, often used when pla placebo or no treatment would be unethical.

Historical Control:
Compares the test drug to historical data or experience, suitable for certain circumstances.


𝗡𝗼𝗻-𝗜𝗻𝗳𝗲𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗦𝘁𝘂𝗱𝗶𝗲𝘀: 𝗣𝗿𝗼𝘃𝗶𝗻𝗴 𝗘𝗾𝘂𝗶𝘃𝗮𝗹𝗲𝗻𝗰𝗲

In cases where using a placebo control is unethical, non-inferiority studies provide an alternative approach.

These studies aim to demonstrate that the new drug is not significantly less effective than an established treatment within a specified margin.


𝗧𝗵𝗲 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗼𝗳 𝗦𝘁𝘂𝗱𝘆 𝗘𝗻𝗱𝗽𝗼𝗶𝗻𝘁𝘀: 𝗖𝗵𝗼𝗼𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗥𝗶𝗴𝗵𝘁 𝗠𝗲𝗮𝘀𝘂𝗿𝗲𝘀

Selecting meaningful endpoints is crucial in assessing drug effectiveness. Endpoints can be:

  • Important outcomes like death or heart attack.
  • Symptoms or measures of function, such as exercise test results.
  • Surrogate endpoints: Laboratory measurements or physical signs that predict clinical benefits.


𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹: 𝗕𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝗨𝗿𝗴𝗲𝗻𝗰𝘆 𝗮𝗻𝗱 𝗖𝗮𝘂𝘁𝗶𝗼𝗻

In certain cases, accelerated approval can be granted based on surrogate endpoints for serious or life-threatening illnesses.

However, post-approval studies are required to verify and describe the drug’s clinical benefits.


Read also:

Leave a Comment